Infectious Diseases papers
Pofolia’s corpus holds 92 papers from Infectious Diseases (1998–2026), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: Clinical Characteristics of Coronavirus Disease 2019 in China (2020, 31,181 citations).
- The 20 papers listed have 261,193 citations between them.
- 16 of the 17 with a known journal quartile appeared in a Q1 journal.
- 9 have a free full text (open access).
- Most frequent journals: New England Journal of Medicine, JAMA, Nature.
- Published between 2013 and 2020.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
Clinical Characteristics of Coronavirus Disease 2019 in China
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 704.52 · 31,181 citations
A study of 1099 COVID-19 patients in China found a 6.1% rate of severe outcomes (ICU admission, mechanical ventilation, or death), with fever and cough being the most common symptoms, though many patients presented without fever and some had no initial radiologic abnormalities.
A Novel Coronavirus from Patients with Pneumonia in China, 2019
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 668.76 · 30,418 citations
A previously unknown betacoronavirus, named 2019-nCoV, was identified in patients with pneumonia linked to a market in Wuhan, China.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Nature · 2020 · Q1 · SJR 19.00 · FWCI 509.38 · 23,375 citations · Open access
A new coronavirus, 2019-nCoV, identified from an outbreak of acute respiratory syndrome in Wuhan, China, shares 96% whole-genome identity with a bat coronavirus and 79.6% sequence identity with SARS-CoV.
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 479.59 · 21,199 citations · Open access
In a Wuhan hospital, 41% of 138 hospitalized pneumonia patients likely contracted 2019-nCoV from the hospital, with 26% requiring ICU care and an overall mortality rate of 4.3%.
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 399.88 · 18,027 citations · Open access
This viewpoint summarizes key epidemiologic and clinical findings from COVID-19 cases in mainland China reported up to February 11, 2020. It also analyzes case trends in relation to government control measures.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 297.38 · 15,595 citations
The BNT162b2 mRNA vaccine candidate demonstrated 95% efficacy in preventing Covid-19 after two doses, with a similar safety profile to other viral vaccines.
A new coronavirus associated with human respiratory disease in China
Nature · 2020 · Q1 · SJR 19.00 · FWCI 279.42 · 12,935 citations · Open access
Researchers identified a novel RNA virus, designated 'WH-Human 1' coronavirus, from a patient with severe respiratory illness in Wuhan, China.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 197.70 · 10,782 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 illness, including severe disease, in a large-scale Phase 3 trial.
Dexamethasone in Hospitalized Patients with Covid-19
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 205.01 · 10,118 citations
Dexamethasone significantly reduced 28-day mortality by 17% (rate ratio 0.83) in hospitalized COVID-19 patients. The benefit was most pronounced in patients requiring mechanical ventilation or oxygen support.
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
JAMA · 2020 · Q1 · SJR 5.00 · FWCI 219.85 · 9,899 citations
A case series of 5700 hospitalized COVID-19 patients in NYC revealed a median age of 63, with hypertension (56.6%), obesity (41.7%), and diabetes (33.8%) as common comorbidities. Overall, 21% died during hospitalization, and 12.2% required mechanical ventilation.
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Science · 2020 · Q1 · SJR 10.00 · FWCI 210.96 · 9,794 citations · Open access
Researchers determined the 3.5-angstrom cryo-EM structure of the 2019-nCoV spike protein in its prefusion state, revealing a predominant conformation with one receptor-binding domain accessible for interaction.
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Cellular Physiology and Biochemistry · 2013 · Q3 · FWCI 140.35 · 8,699 citations · Open access
Human parvovirus B19's capsid protein VP1 significantly inhibits the host cell's Na+/K+-ATPase activity, a key ion pump, by producing lysophosphatidylcholine.
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Eurosurveillance · 2020 · Q1 · SJR 2.00 · FWCI 178.51 · 8,190 citations · Open access
A validated real-time RT-PCR diagnostic workflow for the novel 2019-nCoV has been developed and deployed, capable of detecting the virus and distinguishing it from SARS-CoV without requiring live virus samples.
Dexamethasone in Hospitalized Patients with Covid-19.
DiRROS repository (University of Maribor) · 2020 · FWCI 183.55 · 8,046 citations
Dexamethasone significantly reduced 28-day mortality by 17% in hospitalized COVID-19 patients requiring respiratory support, but showed no benefit for those not needing oxygen.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
Nature Microbiology · 2020 · Q1 · SJR 7.00 · FWCI 169.04 · 7,756 citations · Open access
The Coronaviridae Study Group (CSG) has officially classified the novel coronavirus causing the COVID-19 outbreak as SARS-CoV-2, recognizing it as a distinct species within the Severe acute respiratory syndrome-related coronavirus group.
Remdesivir for the Treatment of Covid-19 — Final Report
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 164.45 · 7,738 citations
Intravenous remdesivir significantly shortened the time to recovery for hospitalized COVID-19 patients with lower respiratory tract infection, reducing it from 15 days to 10 days compared to placebo.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Cell Research · 2020 · Q1 · SJR 6.00 · FWCI 167.70 · 7,386 citations · Open access
Remdesivir and chloroquine have demonstrated in vitro efficacy against the novel coronavirus (2019-nCoV), suggesting potential therapeutic options.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Internet Archive (Internet Archive) · 2020 · 7,341 citations
The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 after two doses in a large Phase 3 trial.
First Case of 2019 Novel Coronavirus in the United States
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 147.94 · 6,399 citations
The first confirmed case of 2019-nCoV infection in the United States is reported, detailing its identification, diagnosis, and clinical progression from mild symptoms to pneumonia.
World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)
International Journal of Surgery · 2020 · FWCI 140.43 · 6,315 citations
The 2019 novel coronavirus (COVID-19), identified as SARS-CoV-2, has caused an unprecedented global outbreak of pneumonia, leading the WHO to declare a global emergency.
Recently added
Design, Synthesis, and Antimicrobial Activity of Novel Cyt- bd Inhibitors Targeting Energy Compensation in Mycobacterium tuberculosis
ACS Medicinal Chemistry Letters · 2026 · Q1
A novel compound, YH-685, potently inhibits the alternative cytochrome bd oxidase (Cyt-bd) in Mycobacterium tuberculosis (Mtb) with an IC50 of 0.45 μM, and when combined with a Cyt-bcc inhibitor, it suppressed virulent Mtb growth in macrophages, achieving inhibition comparable to standard regimens.
Investigating the occurrence of different antibiotic resistance genes in Enterococcus faecalis and Enterococcus faecium isolates from burn patients in Ahvaz, southwest Iran
BMC Microbiology · 2026 · Q1 · SJR 1.00
In burn patients in Ahvaz, Iran, 21.7% of Enterococcus isolates were vancomycin-resistant, with the vanA gene found in 79.1% and vanB in 20.2%. Notably, 79.1% of isolates carried van genes but remained vancomycin-susceptible by standard testing.
Ebola-virus outbreaks are teleconnected with macroclimatic oscillations
Stochastic Environmental Research and Risk Assessment · 2026 · Q1
Four macroclimatic oscillation indices (Pacific Decadal Oscillation, Caribbean Sea Surface Temperature Index, Dipole Mode Index, Quasi-Biennial Oscillation) are spatio-temporally correlated with Ebola virus disease (EBOD) outbreaks in Africa, enabling forecasting.
HIV seroprevalence, treatment cascade outcomes, and determinants of seropositivity in East Africa: a multi-country analysis of population-based HIV impact assessment surveys
BMC Public Health · 2026 · Q1 · SJR 1.00
A multi-country analysis of 132,954 adults in East Africa found HIV seroprevalence ranging from 3.0% to 5.9%, with women and older adults (45-64 years) most affected. While ART coverage is high (96.0%-97.7%), viral load suppression varies (87.6%-94.1%), and undiagnosed infections remain a key challenge.
Determinants of tuberculosis treatment outcomes among TB/HIV co-infected patients in Gambella refugee camps, Western Ethiopia: a case–control study
BMC Infectious Diseases · 2026 · Q1
TB/HIV co-infected patients with no formal education (AOR=9.83), daily laborers (AOR=12.27), TB drug resistance (AOR=2.94), or CD4 count <200 cells/mm³ (AOR=3.46) had significantly worse TB treatment outcomes in Gambella refugee camps.
Coupling Quantum Mechanical Modeling and Molecular Dynamics on Heterogeneous Supercomputers for Studying Distal Mutation Effects on Drug Binding in HIV-1
Journal of Chemical Theory and Computation · 2026 · Q1 · SJR 1.00 · Open access
A new simulation workflow combines GPU-accelerated molecular dynamics (MD) with CPU-based quantum mechanics (QM) to analyze how distant mutations in HIV-1 protease affect drug binding, revealing electronic interaction networks critical for understanding resistance to Darunavir.
Prevalence of vancomycin- and aminoglycoside-resistant pathogenic enterococci in municipal wastewater: A study in northwest Iran
Journal of Water Sanitation and Hygiene for Development · 2026 · Q2
Municipal wastewater in Ardabil, Iran, harbors vancomycin-resistant Enterococcus faecium (3.8% of isolates) and high-level aminoglycoside-resistant strains (23-27.6%), alongside prevalent virulence genes in 71-90% of isolates.
Nano-NucleOTAC-mediated Z-DNA transformation disrupts mycobacterium tuberculosis biofilms and activates antibacterial immunity
Nature Communications · 2026 · Q1 · SJR 4.00
A novel nanoparticle, Nano-NucleOTAC, effectively degrades Mycobacterium tuberculosis (Mtb) biofilms by targeting and transforming Z-DNA, leading to enhanced host immune responses and improved treatment outcomes in mouse models and clinical samples.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 15 | 376 |
| JAMA | Q1 | 5.00 | 818 | 7 | 114 |
| Science | Q1 | 10.00 | 1433 | 3 | 268 |
| BMJ | Q1 | 1.00 | 543 | 3 | 47 |
| Nature | Q1 | 19.00 | 1495 | 2 | 48 |
| Nature Communications | Q1 | 4.00 | 634 | 2 | 94 |
| Clinical Infectious Diseases | Q1 | 2.00 | 414 | 2 | 12 |
| Journal of Virology | Q1 | 1.00 | 338 | 2 | 3 |
Every journal in Infectious Diseases (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app